ARDS Meeting Notes
The ARDS provides participants with a Meeting Notes PDF which includes most slide presentations from the meeting. The Meeting Notes are taken and assembled by talented and rising retinal stars. They attend every talk and capture the essence of the vigorous post-talk discussion, for which the ARDS is deservedly famous.
Please email ards@medconfs.com to request a copy of the Meeting Notes. Be sure to include the year(s) requested.
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
| Past ARDS Speakers “The list is huge. Many of us are very cognizant of the fact that we truly do stand on the shoulders of giants. In retina, many of the giants came regularly to that meeting. I remember very vividly being there with everyone from Tom Aaberg, Sr. to Steve Charles to Don Gass, many of the real luminaries in our field… Here was an opportunity to not only listen, but to stand up in front of your peers and probe into important clinical questions in a forum that not only permitted it, but encouraged it.” David Parke, II |
|
|---|---|
| Records per page: | |
| 2020 48th Annual Meeting | |
| Giovanni Staurenghi, MD | SD-OCT and SS-OCT: What is the Impact? |
| Christina Y. Weng, MD, MBA | Subretinal Gene Therapy |
| Christina Y. Weng, MD, MBA | Teleretinal Screening for Diabetic Disease |
| Panel Discussion | Advanced Retinal Therapy |
| Panel Discussion | Impact of Advanced Imaging and AI on Retina |
| Panel Discussion | Surgical Advances – The ARDS Perspective |
| 2019 47th Annual Meeting | |
| Yale L. Fisher, MD | The Essence of Diagnostic Ultrasonography |
| Harry W. Flynn, Jr., MD | Endophthalmitis: Clinical Cases and Management Strategies |
| Harry W. Flynn, Jr., MD | OCT-Angiography in Diabetic Retinopathy |
| Harry W. Flynn, Jr., MD | Retinal Breaks: Clinical Cases, Complications and Treatment Options |
| Allen C. Ho, MD | Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise |
| Mark W. Johnson, MD | Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions |
| Mark W. Johnson, MD | Pathogenesis and Treatment of Cavitary Optic Disc Maculopathy |
| Peter K. Kaiser, MD | New Therapies for DME |
| Peter K. Kaiser, MD | New Therapies in Wet AMD |
| Szilárd Kiss, MD | Machine Learning and Artificial Intelligence for Diagnosing Retinal Disease |
| Szilárd Kiss, MD | Operationalizing Big Data for Diabetic Retinopathy Screening in New York City |
| Timothy G. Murray, MD, MBA | Vitreoretinal Surgery: When You Do What Others WON’T |
| Anton W. Orlin, MD | Management of Retained Lens Fragments and Secondary IOL Placement |
| Hugo Quiroz-Mercado, MD | Can We Modify the Natural History of Intermediate Age-Related Macular Degeneration? |
| Hugo Quiroz-Mercado, MD | What Have We Learned from Anti-VEGF in ROP? |
| David HW Steel, MBBS, MD, FRCOphth | ILM Peeling in Macular Hole Surgery - When and How? |
| David HW Steel, MBBS, MD, FRCOphth | Submacular Hemorrhage in AMD - How Should We Manage It? Techniques and Decisions |
| Panel Discussion | Advances in Vitreoretinal Surgery: Heads Up, ILM Flaps, IntraOp OCT and All the Rest |
| Panel Discussion | Pharmacotherapy of AMD, DME, and RVO: What Are We Doing in 2019? |
| PREV | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 | NEXT |
